Vital statistics A B S T R A C T This paper describes the collection, standardisation and checking of cancer survival data included in the EUROCARE-4 database. Methods for estimating relative survival are also described. Incidence and vital status data on newly diagnosed European cancer cases were received from 93 cancer registries in 23 countries, covering 151,400,000 people (35% of the participating country population). The third revision of the International Classification of Diseases for Oncology was used to specify tumour topography and morphology. Records were extensively checked for consistency and compatibility using multiple routines; flagged records were sent back for correction. An algorithm assigned standardised sequence numbers to multiple cancers. Only first malignant cancers were used to estimate relative survival from registry, year, sex and age-specific life tables. Age-adjusted and Europe-wide survival were also estimated.
1.
Introduction EUROCARE, which started in 1990, is the largest international collaborative population-based study on the survival of cancer patients. In addition to numerous papers on particular aspects of cancer survival, the study has published three major monographs on European cancer survival, one for each of the diagnosis periods 1978-1985, 1 1985-1989 2 and 1990-1994 . 3 The study has involved progressively more countries and cancer registries (CRs) over time, and has now archived data on over 13,800,000 cancer cases. The EUROCARE database is a unique and valuable resource for analysing and comparing cancer outcomes not only across European countries and regions, but also over time (since 1978) ; it has, at the same time, accumulated a large and precious database on outcomes for rare tumours. 4 The current EUROCARE round, EUROCARE-4, gathered incidence data from 93 European CRs on patients diagnosed from 1978 up to 2002, with vital status information available up to 31st December 2003 or later. Two major novelties have been introduced in EUROCARE-4. First, the Third Revision of the International Classification of Diseases for Oncology (ICD-O-3) was used to specify cancer topography and morphology. 5 Second, in addition to the traditional cohort survival analysis of patients diagnosed in 1995-1999 and followed-up over time, we now present a period survival analysis, which includes the most recent cases (diagnosed in [2000] [2001] [2002] for which the minimum follow-up of 5 years is not available and for which survival in the missing years was estimated from the survival experience of patients diagnosed in the previous years. Summary EUROCARE-4 cohort 6 and period 7 analyses, by country, for selected cancer sites had been published previously. The present issue of the European Journal of Cancer, constituting the fourth general EUROCARE monograph, provides a more exhaustive presentation of the EUROCARE-4 estimates. The present paper describes the characteristics of the EUROCARE-4 database in detail, the methods used to standardise and check the data and the methods used to perform the survival analyses.
The EUROCARE-4 database: participating CRs and populations covered
Ninety-three CRs from 23 European countries contributed to EUROCARE-4, 83 contributed data on cancers diagnosed in both children (0-14 years) and adults (15-99 years) (Table 1a) and 10 contributed data on childhood cancers only (Table  1b ). All these registries contributed cases for the survival analyses of cohorts diagnosed in 1995-1999. 8 Registries meeting the criteria described in Brenner et al. 9 were selected for the period survival analyses.
Thirteen countries have national cancer registration: Austria, Denmark, Finland, Iceland, Ireland, Malta, Norway, Slovenia, Sweden, England, Northern Ireland, Scotland and Wales. Germany has national coverage for childhood cancers only. The remaining countries have cancer registration between 8% and 58% of their populations, with the conspicuous exception of Germany, where only 1.3% of the adult population is covered. The mean population covered over the period 1995-1999 was about 151,407,000, corresponding to 35% of the population of the countries participating in EUROCARE-4 and 30% of the population of the European Union (excluding Norway, Switzerland and Iceland which are not EU members).
Thirty-two more CRs were included in EUROCARE-4 than in EUROCARE-3. This resulted in three new countries being represented (Belgium, Ireland and Northern Ireland) and increased coverage for several others (from 62% to 100% for England, 15% to 25% for Italy, 2% to 10% for France, 12% to 27% for Switzerland and 8% to 100% for Austria). As in the previous EUROCARE publications, results by country for United Kingdom (UK) are presented separately for England, Scotland, Wales and Northern Ireland. Five CRs involved in the previous EUROCARE studies are not included in EUROCARE-4, either because they did not send in updated data by the final deadline (Estonia and Slovakia) or because they no longer participate in EUROCARE.
Some CRs have changed their catchment areas since EUROCARE-3. Since 1996 the English East Anglia CR covered Bedfordshire (previously covered by Thames CR). The Northern and Yorkshire CR covered only Yorkshire from 1978 to 1997, but the whole of Northern England since 1998. The English South and West Registry now includes the populations of 'Wessex' and South-West England. The Thames CR catchment area now (since 1985) includes the territories of the old North and South Thames regions.
Twelve CRs (specialised and general) from France, Italy, Spain and Switzerland sent data only for one or more specific cancer sites, so for these countries the extent of national coverage varied with the cancer site (Table 1a ). The populations of Calvados and Cote d'Or are each covered by two CRs (digestive tract and other in Calvados; digestive tract and haematopoietic system in Cote d'Or). All CRs providing data only for the selected sites were excluded from the all cancers combined analyses.
The population covered by the Tyrol CR is also included in the Austrian National CR. The English National database, provided by the UK Office for National Statistics, gathered data from all English CRs in the period [1995] [1996] [1997] [1998] [1999] [2000] [2001] [2002] . For the period 1995-1999 the nine regional English registries overlap completely with the English National database, and their data were used for the analyses (on both regional and national scale). However, the English National database was used for the country-specific period survival analyses, 9 since some of the regional English registries contributed data on diagnoses in 2000-2002 not as individual registries but only as part of the National database.
Data collection and standardisation

Study protocol and data collection
The EUROCARE-4 study protocol 10 required the collection of the following items for each cancer case: sex; dates of birth, diagnosis and last ascertainment of vital status; vital status; codes indicating cancer topography, morphology and behaviour; sequence number of the tumour to distinguish first from subsequent primary cancers; whether the diagnosis was microscopically verified; and anonymous patient identification number. The latter number uniquely identifies each 
5 ( 2 0 0 9 ) 9 0 9 -9 3 0 patient, and was used to facilitate the review and correction of errors and inconsistencies. Date of case registration and basic information on stage at diagnosis were also requested, but were not compulsory since they were not always available to all CRs. A data field on each record indicated whether it had been subjected to the checking routines of the International Agency for Research on Cancer (IARC).
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Registries participating in the previous EUROCARE rounds were asked to send in their entire dataset, so that the updated information on the cases diagnosed before the EUROCARE-4 round was available. The data were archived in a dedicated server at the Istituto Superiore di Sanità , Rome, which is the data analysis centre for EUROCARE.
Standardisation of tumour identification numbers
Only first primary tumours were included in the survival analyses, although data on multiple tumours were collected and A Denmark provided data for the 45 specific cancer sites listed in Table 2 1996 -1999 . l Mean population 1998 -1999 checked, and for the first time the effects of the inclusion of multiple tumours on the relative survival estimates were evaluated. 12 Procedures for assigning tumour sequence numbers to multiple primary cancers in a single person are not uniform across CRs, and this may have an impact on the survival estimates, due to the lack of standardisation in the selection of first tumour. For this reason, we assigned a recoded tumour sequence number, generated from the patients' identification number (to identify the patient), the behaviour, site and morphology (to identify the tumour and whether it is malignant) and the month and year of diagnosis (to determine the order of diagnosis of multiple primaries). Recoded tumour sequence numbers followed separate numbering orders for: (a) malignant tumours (excluding non-melanoma and non-sarcoma skin cancers) and (b) non-melanoma and non-sarcoma malignant skin cancers plus benign/in situ tumours. Not all CRs provided data on the latter category. Since patient identification numbers are required to generate recoded tumour sequence numbers, the latter could not be generated for the cases from 14 CRs that provided tumour rather than patient identification codes. For these CRs, the original tumour sequence number was used instead. The original tumour identification number was also preferred for (a) CRs providing data on certain cancer sites only (Cote d'Or Haematologique, Denmark, Granada, Grisons and Zurich) and (b) CRs in operation prior to 1978 (Iceland, Sweden and Finland) . The latter CRs, with long operating times, have cancers archived that were diagnosed earlier than the earliest cases archived in EUROCARE. So, from their data the order of diagnosis of multiple tumours in a single person can be detected with a higher level of precision than from the EURO-CARE database.
We calculated recoded tumour sequence numbers for 61 CRs. For these CRs, we compared the proportions of multiple tumours calculated from recoded and original tumour identification numbers. We found that the percentages were often closely similar (absolute differences were on average 0.1 and never exceeded 2 percentage points) indicating that most CRs followed similar procedures to those we followed for identifying the multiple tumours and for determining the order of diagnosis. By contrast, when we considered the long-established registries of Iceland, Sweden and Finland, as expected, the number of multiple primaries determined from original tumour identification numbers was considerably greater than that determined from recoded identification numbers.
2.3.
Standardisation of topography and morphology codes
The EUROCARE-4 protocol 10 stipulates that topography should be specified according to ICD-9, ICD-10 or ICD-O; and that morphology should be according to ICD-O-2 or ICD-O-3. ICD-O was in fact mainly used to code topography, followed by ICD-10; ICD-9 was used rarely. The diagnosis period was the main determinant of whether morphology was specified by ICD-O-2 or ICD-O-3. ICD-O-3 was chosen as a reference for coding the topography and morphology of all EURO-CARE-4 cases. ICD-O-3 was also used in the subsequent checking procedures, so as to ensure the maximum compatibility with IARC data-checking programs. Since most CRs provided topography and morphology codes in this form, the amount of trans-coding required was fairly limited. ICD-O-2 morphology codes were translated automatically to ICD-O-3 using a trans-coding table.
10 A similar table was used for an automatic conversion of the few cases with ICD-O-1 codes. ICD-9 and ICD-10 site codes were converted into ICD-O-3 topography codes using specific trans-coding tables.
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ICD-9/10 codes indicating benign, in situ or borderline behaviour were translated only after an automatic checking that they were compatible with the behaviour of the corresponding ICD-O-3 categories. ICD-9/10 codes with the morphology information were checked in the same way. Compatible codes are shown in Table A1 (Appendix). Incompatible ICD-9/10 codes were not translated, and during subsequent data checking these were treated as topography-behaviour or topography-morphology inconsistencies. When the morphology field was blank, the morphological information carried by ICD-9/10 topography codes was not lost but was used to automatically impute the corresponding morphology code.
Forty-five major cancer sites
We considered 45 major cancer sites, as well as all cancers combined ) consisting of all malignant cancers except nonmelanoma and non-sarcoma skin cancers ) in the EURO-CARE-4 analyses. The ICD-O-3 codes contributing to the 45 major sites are shown in Table 2 . Usually only malignant cancers were included within these sites: the few exceptions are specified in Table 2 . With few exceptions these 45 cancer sites correspond to those used in the previous EUROCARE studies to ensure the maximum comparability. These sites are also closely similar to those used by the Surveillance, Epidemiology and End Results (SEER) programme 13 for presenting the latest United States (US) Cancer Statistics Reviews. 14 However, there were some differences: in EUROCARE, the colon and rectum site included anus, anal canal and not otherwise specified intestinal sites; lung included trachea and bronchi and soft tissues included heart. Different definitions were also used for bladder, liver and acute myeloid leukaemia. Finally, choroid melanoma was not included in SEER but is present in EUROCARE.
Data quality control
Automated procedures checked each data field and combinations of fields in each case record, including benign and in situ cases, and cases with diagnosis date prior to 1995. The consistency of each field was checked first by comparing with the valid ranges contained in the EUROCARE-4 protocol. 10 Topographies and morphologies were checked against ICD-O-3 lists.
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Checks on combinations of data fields concerned:
• Consistency between dates of birth, diagnosis and followup.
• Consistency of site-morphology combinations. The standard IARC routines 11 were applied first, followed by those of EUROCARE (Table A2 Appendix).
• Consistency of age-site, age-morphology, sex-site and sexmorphology combinations. Unlikely combinations were checked against IARC criteria.
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• Consistency of morphology-behaviour combinations. Combinations not listed in ICD-O-3 classification were flagged as unlikely.
Records with invalid fields or impossible or unlikely combinations were sent back to the CRs for revision. Records returned after revision were re-checked. A specific field kept track of checking requests and their results, which were used to decide the eventual fate of the record. Duplicate records were not admitted to the EUROCARE-4 database. Missing, invalid or inconsistent date, sex, site, morphology and behaviour fields were coded as major errors. Records with major errors entered the EUROCARE-4 database, but were excluded from the survival analyses. Unlikely combinations of age/ sex/site/morphology, confirmed after review by the CR, as well as unlikely combinations of morphology and behaviour were coded as minor errors and included in both the database and the survival analyses.
The numbers of cases included in the EUROCARE-4 database, for each CR, with diagnosis period, as well as the summary results of the checking procedures are presented in Table 3 , separately for the all ages and childhood CRs. Overall about 13,815,000 cases, diagnosed from 1978 to 2002, were admitted to the EUROCARE-4 database.
After checking and correcting where possible, 97.8% of the admitted records were error free, 0.22% contained major errors and the rest were minor errors. For CRs covering all ages, most (70%) of the 271,102 records with minor errors had unlikely behaviour-morphology combinations. For the specialised childhood CRs, unlikely combinations of other variables formed most (98%) of the 3,663 minor errors. Overall, 21,409 minor errors (11% of all minor errors) were due to unlikely behaviour-morphology combinations in malignant cases. Of the total 171,830 non-malignant cases with unlikely behaviour, about 87% (150,128) came from Norway. Of these, 60% were cervix uteri carcinomas of uncertain behaviour (ICD-O-3 code: 8010/1) and 7% were skin tumours of uncertain behaviour (NOS squamous cell carcinoma) (ICD-O-3 code 8070/1).
Overall 8.4% of tumours were benign/in situ, with a marked variation between the registries: from 30% in Norway to zero or almost zero in many French and Italian CRs. These differences reflect disparate practices for the collection or provision of data on non-malignant tumours, rendering cross-registry analyses of these neoplasms particularly difficult. Most nonmalignant tumours occurred at the uterine cervix (50%), bladder (10%) and large bowel (8%) sites.
Data changes after 2007
The analyses presented in this issue of the European Journal of Cancer were carried out in February 2008, eight months after the first two EUROCARE-4 summary papers 6, 7 had been drafted. During this period, the datasets of several CRs were modified. Some changes consisted of updates or late corrections: queried records from the Swedish registry were returned; 2000-2002 diagnosis period data from the Cote d'Or haematological registry were included; up to date follow-up information arrived from the North Netherlands registry. Other changes were made to resolve the problems that emerged during the analyses. The most important of these was to change the date of closure of follow-up for the Austrian national CR from 31st December 2003 to 31st December 2002 since vital status information during 2003 was incomplete, selectively so for the patients still alive. Corrections were also made to the multiple tumour indicators for the CRs of Finland, Iceland and Sweden to take account of information on the cancers diagnosed prior to 1978, that were available to these registries but not present in the study database. 9590-9596, 9670-9671, 9673, 9675, 9678-9680, 9684, 9687, 9689-9691, 9695, 9698-9702, 9705, 9708-9709, 9714-9719, 9727-9729 
4.
Data quality indicators
The main data quality indicators for the adult cases diagnosed from 1995 to 2002 are presented in Overall, 2.7% of the cases were DCO, ranging from zero to 10.2% in Austria, 12.5% in Wales and 14.1% in Thames. Zero proportions were found for the CRs that do not use the information of death certificates in the registration (such as those in France, Portugal and Sweden). Overall, only 0.4% of valid primary cancers were discovered at autopsy. However, proportions were considerably higher in Basel (2.9%), Sweden (2.2%) and West Bohemia (5.7%).
About 90% of the 5,278,670 cases included in the survival analyses were microscopically verified, although again the proportion varied widely with country. Excluding the outlier Wales, for which a large proportion of pathology records were not available to the registry, the proportion with the microscopic verification varied from 74% in Cracow to 100% in specialised CRs.
The proportion of patients lost or censored before 5 years is an important indicator of data quality for survival estimates. Closing follow-up at 31st December 2003 allowed at least 5-years of follow-up for the cases diagnosed from 1995 to 1998. Considering only the cases diagnosed in this period, the proportion alive but followed up for less than 5 years was slightly above 1% (Table 4 , last column). Notable exceptions were CRs with the earlier follow-up closing date of 31st December 2002 (Austria, Saarland and West Bohemia) and CRs with non-negligible numbers of cases censored in 2002 or before (Cote d'Or Haematological, East Anglia and Varese). If only passive follow-up methods are used the proportion of censored cases is null by definition, so this indicator cannot be used to assess the follow-up completeness. Table 5 shows the proportions of microscopically verified (histological or cytological) cases, by CR, for selected common cancers diagnosed from 1995 to 2002. The extent of microscopic verification depends on the accessibility of the cancer to biopsy, whether surgery was performed, and also the availability of the pathology reports to CRs. The lowest overall proportions of microscopic verification were for rapidly fatal cancers: pancreas (62.7%), brain (78.2%) and lung (83.4%). By contrast, over 95% of skin melanoma, breast and non-Hodgkin's lymphoma cancers were verified. Microscopic verifications were typically 5% to 10% points higher in EUROCARE-4 than in EUROCARE-3 (diagnosed in 1990 EUROCARE-3 (diagnosed in -1994 ).
16 Table 6 shows crude (i.e. non-age-standardised) 5-year relative survival by country for selected poor prognosis cancers (oesophagus, liver, pancreas, lung and pleura) diagnosed in 1990-1994 (EUROCARE-3) compared with those diagnosed in 1995 -1999 . Unusually high survival rates for these rapidly fatal cancers suggest an incomplete life status ascertainment (or possibly inaccurate diagnoses). We defined high survival outliers as those countries in which the lower bound of the 99% confidence interval (CI) for survival exceeded the upper bound of the 99% CI for survival of the pool of European CRs. Using this method, implausibly high survival was found in Austria for pancreatic and lung cancers, and in Belgium for oesophageal, pancreatic and lung cancers ( Table 6 , figures in bold). Exceptionally high survival levels were observed for oesophagus in Germany, for pancreas in Portugal and pleura in Poland. Both exceptionally high survival and exceptionally low survival were observed in Iceland, due to the small population size and correspondingly high random variability. It is encouraging that follow-up problems identified in Spain and Wales in EUROCARE-3 using this method 16 seem to have been overcome in the present EUROCARE round. In Spain, for example, CRs now have access to the Spanish National Death Index, which is likely to have contributed to improving death ascertainment in that country. 17 
Methods of survival analysis
The principal indicator provided by EUROCARE is relative survival. Conventionally expressed as a percentage, relative survival is the ratio of the observed survival in a group of patients to the expected survival in a comparable group of individuals from the general population. Relative survival is widely used for international comparisons ) in lieu of cause-specific survival ) in order to remove the risk of competing mortality (risk of death for causes other than cancer), which varies between CR areas and countries. The standard cohort approach was used to estimate the 5-year relative survival for patients diagnosed in 1995-1999. 8 The so-called period approach, introduced by Brenner et al., 18 was used to estimate the relative survival in 2000-2002. 9 The cohort and period survival estimates were obtained using the SEER * Stat software. 19 Relative survival was estimated using the Hakulinen method 20 from sex-, age-and calendar year-specific life tables for each CR population.
Relative survival can exceed 100%, indicating that the survival in the group of cancer patients is higher than the survival expected in the matched group from the general population. This can happen when information on death is missed by the registry, or by chance in small-size populations. However, it can also occur if patients are cured and subsequently have a healthier lifestyle or are better treated for co-morbidities than the reference population. Standard errors of mean survival estimates were calculated with the Greenwood formula, as incorporated in the SEER * Stat software. To obtain 95% CI the data were logarithmically 1990-1994 1995-1999 1990-1994 1995-1999 1990-1994 1995-1999 1990-1994 1995-1999 1990-1994 1995-1999 transformed, so that the lower bound of the CI was always positive.
Registry-specific life tables
Detailed information on all-causes mortality by age, sex and calendar year for each CR population is essential for estimating the relative survival denominators. Incomplete data on all-causes mortality were provided by the registries participating in EUROCARE. It was therefore necessary to use mathematical interpolation methods to obtain life tables for each year of age between 0 and 99 years and for each calendar year between 1978 and 2004. Several methods were used for these interpolations 21, 22 : the fraction method to estimate life expectancies for missing calendar years; the polynomial Elandt-Johnson method to obtain life tables for each year of age from those for 5-year age classes 23 ;
the adult age method to estimate the probability of death at ages 75 and over using the Gompertz distribution and the Ewbank adaptive method to derive regional from national life tables 22 (the latter applied to English CRs). Registry-specific information on life tables data and interpolation methods are given in [10] .
Age adjustment of survival
Age is a major determinant of cancer survival, and in international comparisons it is necessary to take account of the different age structures of the populations compared. Relative survival estimates for all ages combined were age-adjusted using the direct method and the international Cancer Survival Standard (ICSS) age distributions proposed by Corazziari et al., 24 who used multivariate analysis of EUROCARE-2 data to define the smallest possible number of standard cancer patient populations and to provide agestandardised survival values close to the crude ones for the largest possible number of cancer sites. Three different standard age distributions were identified according to the age pattern of incidence of the cancer: one for the cancers mainly of young adults (e.g. testicular cancer or Hodgkin's lymphoma), one for the cancers whose incidence varies little with age (e.g. cervix uteri or thyroid cancers) and one for the cancers whose incidence increases with age (the majority of cancers). The ICSS weightings used, by age class and group of cancer sites, are shown in Table A3 (Appendix).
In the previous EUROCARE studies, survival rates were standardised using the empirical cancer site-specific age distributions of European incident cases in the last available period of diagnosis. Compared to the previous system, the ICSS weightings have the advantages of being easier to apply and of remaining constant over time, because they are not dependent on the age distribution of the cases in examination.
The variances of the age-adjusted survival estimates were calculated by directly weighting the corresponding age-specific variances. Ninety-five percent CIs were estimated assuming that age-adjusted survival estimates had normal distributions after logarithmic transformation.
Age-adjusted survival estimates could not be calculated when early censoring or lack of cases resulted in missing values in one or more age classes. This usually occurred with small populations or with relatively rare cancer sites (in all or in some age groups). Occasionally in such circumstances, country-specific age-adjusted survival may be implausibly lower or higher than the crude survival, because small numbers of cases in highly weighted age groups all survive or all die. In such situations the SEER * Stat software does not produce a standard error, and the statistical uncertainty is not accurately reflected in the CIs of age-adjusted estimates. This is noted, when it occurs, in the relevant tables of this monograph. 8 
Average European survival
Although a considerable fraction of Europe is now covered by EUROCARE (35% of the population of the 23 participating countries), the fraction of the population covered in each participating country varies from 1.3% to 100% (Tables 1a  and 1b (Italy, Malta, Portugal, Slovenia, Spain) . Pooled region-specific survival was then estimated, assuming the population covered by registration to be representative of the whole region. The European average was obtained after directly weighting the region-specific survival estimates with the mean population of each region over 1995 -1999 . During 1995 -1999 European mean survival estimates for all ages combined were age-adjusted using the same ICSS standard as used for country-specific estimates. Standard errors of European survival, with 95% CI, were estimated by the same method as used for age-adjusted country-specific survival.
Discussion
EUROCARE survival estimates are increasingly used as a reference for comparing with those of national 25 and international studies. 26 This paper provides detailed information on the standardisation and checking procedures used to ensure that the EUROCARE-4 data are as error free as possible. Data quality indicators and statistical methods used are also given to assist the interpretation of EUROCARE-4 results and comparison with survival figures from other studies.
When EUROCARE started in 1990 it obtained data from 30 CRs in 11 European countries. Since then the numbers of participating CRs and countries, and the proportion of the European population represented, have increased steadily with each round. The EUROCARE-4 round now covers 30% of the EU population and 35% of the population of the participating countries.
Estonia and Slovakia, classified within Eastern Europe, did not send in data by the final deadline so they are not included in the current EUROCARE-4 analyses, with the additional consequence that Eastern Europe as a whole is under-represented. Updated datasets from Estonia and Slovakia were received during the preparation of this manuscript.
Germany, the largest EU country, remains under-represented with only a single participating adult CR covering just 1.3% of the national population. However, new CRs are currently being set up in Germany 27 and other countries, and we expect the proportion of the European population covered will further increase in future EUROCARE rounds. The latest (third) revision of the International Classification of Diseases for Oncology was, for the first time, used to specify cancer topography, morphology and behaviour in the entire EUROCARE-4 dataset. In fact most CRs sent in data already coded (or recoded) in ICD-O-3, so the amount of recoding that had to be done by EUROCARE was limited. ICD-O-3 started being used on a large scale from 2000 on ) just after the core period of the present study, so most cases were originally coded according to the previous systems and locally trans-coded into ICD-O-3. The most important changes in ICD-O-3 compared to the previous versions concern the haematological malignancies, whose definition is now more closely linked to the classification used in clinical settings. 28 The data checking and validation processes used in EURO-CARE-4 were simpler than those used in the previous EURO-CARE rounds. Firstly, the checking procedures were revised and made consistent with those proposed by IARC.
11 Also most of the EUROCARE specific checks have been incorporated into the IARCcrg software now used by most European CRs; as a consequence a negligible proportion of records was excluded for major errors. Data quality indicators indicate that the quality of EUROCARE-4 data was satisfactory as a whole and had improved compared to previous rounds. However, the proportion of DCO cases was rather high for some CRs, particularly the Austrian national registry and some UK registries, indicating problems with case detection. The extent to which survival indicators in CRs with a high proportion of DCO cases are biased can only be assessed with more specific analyses based on the local data. A recent study 29 comparing the Thames and Finnish CRs found that the decrease in survival in Thames produced by adjusting for DCO cases was largely offset by an increased survival produced by adjusting for the incompleteness of case ascertainment. We compared relative survival estimates for selected poor prognosis cancers in EUROCARE-3 and EUROCARE-4 (Table 6) to highlight the potential problems in the completeness of follow-up. Incomplete ascertainment of vital status mainly results in dead patients being misclassified as alive so that the survival is overestimated and the overestimate is likely to be particularly marked for rapidly fatal cancers. We found that follow-up completeness had improved markedly for the Spanish registries and the Welsh national registry compared to EUROCARE-3. However, our outlier analysis indicated that the Austrian and Belgian CRs did not have satisfactorily complete follow-up.
Estimation of overall European survival involved initial grouping of CRs into five European regions (Northern Europe, UK and Ireland, Eastern Europe, Central Europe and Southern Europe), followed by calculating the weighted average of regional survival estimates using the region-specific populations as weightings. Only the populations of countries participating in EUROCARE contributed to the regional weightings. This procedure differs from that used in EURO-CARE-3, which weighted country-specific survival estimates by respective country populations so giving excessive weight to countries with large populations and small cancer registration coverage, such as Germany or, to a lesser extent, France. Furthermore, because the error of small samples is large, it also introduces a large error to the overall European estimate.
Weighting region-specific, rather than country-specific, survival estimates limits the problems described above, and in particular reduces the standard error of the European-wide estimates.
The populations of UK/Ireland and Northern Europe were fully represented in EUROCARE-4. The participating countries of Central and Southern European had, respectively, a coverage of 18% and 26% of their populations, and were assumed to adequately represent those populations. Just two countries were included in Eastern Europe, whose population is unlikely to be adequately represented in the study. The Europewide survival estimates provided in this monograph are not fully comparable with those of the previous EUROCARE studies, [1] [2] [3] not only because the populations covered do not perfectly overlap, but also because country-weighted survival estimates were used. Effective monitoring of the impact of new diagnostic and therapeutic procedures requires the availability of regularly updated population-based indicators. For this reason, a major effort was made to produce period survival estimates for patients diagnosed up to 2002 on the widest available European dataset. We therefore expect the new EUROCARE analyses to be of even more interest to oncologists, clinicians and health planners than the previous EUROCARE studies.
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Austria: W Oberaigner (Tyrol Cancer Registry); M Hackl (Austrian National Cancer Registry); Belgium: E Van Eycken; Martine Verstreken (Flemish Cancer Registry), Czech Republic: Table A3 -International Cancer Survival Standards (ICSS) used for standardising survival by age according to cancer site. Age classes and weighting for three types of cancer incidence age patterns.
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Age classes Weightings Cancer sites 3 15-44, 45-54, 55-64, 65-74, 75-100 60, 10, 10, 10, 10 Testis, Hodgkin's disease, acute lymphatic leukaemia 2 [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] 17, 21, 20, 14 Nasopharynx, soft tissues, melanoma, cervix uteri, brain, thyroid 
